BRPI0514723B8 - composições contendo componentes de agonista alfa-2-adrenérgico - Google Patents

composições contendo componentes de agonista alfa-2-adrenérgico

Info

Publication number
BRPI0514723B8
BRPI0514723B8 BRPI0514723A BRPI0514723A BRPI0514723B8 BR PI0514723 B8 BRPI0514723 B8 BR PI0514723B8 BR PI0514723 A BRPI0514723 A BR PI0514723A BR PI0514723 A BRPI0514723 A BR PI0514723A BR PI0514723 B8 BRPI0514723 B8 BR PI0514723B8
Authority
BR
Brazil
Prior art keywords
adrenergic agonist
alpha
components
agonist components
compositions containing
Prior art date
Application number
BRPI0514723A
Other languages
English (en)
Portuguese (pt)
Inventor
Olejnik Orest
G Bakhit Peter
Graham Richard
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0514723A publication Critical patent/BRPI0514723A/pt
Publication of BRPI0514723A8 publication Critical patent/BRPI0514723A8/pt
Publication of BRPI0514723B1 publication Critical patent/BRPI0514723B1/pt
Publication of BRPI0514723B8 publication Critical patent/BRPI0514723B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0514723A 2004-08-27 2005-08-17 composições contendo componentes de agonista alfa-2-adrenérgico BRPI0514723B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/928,906 2004-08-27
US10/928,906 US20050026924A1 (en) 2000-07-14 2004-08-27 Compositions containing alpha-2-adrenergic agonist components
PCT/US2005/029707 WO2006026215A1 (en) 2004-08-27 2005-08-17 Compositions containing alpha-2-adrenergic agonist components

Publications (4)

Publication Number Publication Date
BRPI0514723A BRPI0514723A (pt) 2008-06-24
BRPI0514723A8 BRPI0514723A8 (pt) 2018-05-08
BRPI0514723B1 BRPI0514723B1 (pt) 2020-12-22
BRPI0514723B8 true BRPI0514723B8 (pt) 2021-05-25

Family

ID=35589384

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514723A BRPI0514723B8 (pt) 2004-08-27 2005-08-17 composições contendo componentes de agonista alfa-2-adrenérgico

Country Status (8)

Country Link
US (1) US20050026924A1 (enExample)
JP (2) JP2008511628A (enExample)
AU (1) AU2005280259A1 (enExample)
BR (1) BRPI0514723B8 (enExample)
CA (1) CA2578784C (enExample)
MX (1) MX2007002383A (enExample)
NZ (1) NZ599669A (enExample)
WO (1) WO2006026215A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320911B1 (en) 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110251285A1 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
CN110662543A (zh) * 2017-03-23 2020-01-07 灰色视觉公司 用于治疗眼部疾病的药物和组合物
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP6603785B2 (ja) * 2017-12-08 2019-11-06 千寿製薬株式会社 水溶性高分子を含む水性液剤
JP6730500B2 (ja) * 2018-10-01 2020-07-29 千寿製薬株式会社 水性液剤
JP6797992B1 (ja) * 2019-09-30 2020-12-09 千寿製薬株式会社 水性液剤
JP6901619B2 (ja) * 2019-09-30 2021-07-14 千寿製薬株式会社 水性液剤
GR1010024B (el) 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
JP7002692B2 (ja) * 2020-11-18 2022-02-04 千寿製薬株式会社 水性液剤

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154119B (de) * 1961-11-30 1963-09-12 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 2-(2', 4', 6'-Trimethylbenzyl)-1, 3-diazacyclopenten-(2) und seinen Salzen
US3278447A (en) * 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3994828A (en) * 1973-06-07 1976-11-30 Dynapol Corporation Nonabsorbable antioxidant
US4499077A (en) * 1981-02-03 1985-02-12 Stockel Richard F Anti-microbial compositions and associated methods for preparing the same and for the disinfecting of various objects
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
IL92351A (en) * 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5352796A (en) * 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JP3527256B2 (ja) * 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
DE69431880T2 (de) * 1993-10-13 2003-09-18 Allergan, Inc. Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
SG44628A1 (en) * 1993-12-17 1997-12-19 Procter & Gamble 6-(2-imidazolinylamino) Quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US5994110A (en) * 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
CN101897704B (zh) * 2000-07-14 2014-10-29 阿勒根公司 含有α-2肾上腺素能激动剂的组合物
JP2004503593A (ja) * 2000-07-14 2004-02-05 アラーガン、インコーポレイテッド 増大した溶解度を持つ治療活性成分を含む組成物
US20020198210A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions

Also Published As

Publication number Publication date
BRPI0514723A8 (pt) 2018-05-08
JP2012246304A (ja) 2012-12-13
WO2006026215A1 (en) 2006-03-09
AU2005280259A1 (en) 2006-03-09
BRPI0514723B1 (pt) 2020-12-22
JP2008511628A (ja) 2008-04-17
CA2578784A1 (en) 2006-03-09
NZ599669A (en) 2013-11-29
US20050026924A1 (en) 2005-02-03
BRPI0514723A (pt) 2008-06-24
CA2578784C (en) 2015-02-17
MX2007002383A (es) 2007-05-15

Similar Documents

Publication Publication Date Title
NO20024221D0 (no) Blandinger inneholdende alfa-2-adrenerge agonistkomponenter
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0514723B8 (pt) composições contendo componentes de agonista alfa-2-adrenérgico
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EA201000774A1 (ru) Ингибиторы бета-лактамазы
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
BRPI0617159A2 (pt) COMPOSTOS DE PIRIDOPIRIMIDINONE INIBIDORES DE PI3Ka, COMPOSIÇÕES QUE OS CONTEM E PROCESSO PARA PREPARO
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
MEP52808A (en) Aminoheteroaryl compounds as protein kinase inhibitors
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
CL2007003791A1 (es) Compuestos derivados de piperidina, inhibidores de la proteina quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para inhibir el crecimiento celular anormal.
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
BRPI0606379A2 (pt) triazolftalazinas
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
NO20082191L (no) Forbindelser
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
AR055570A1 (es) Polimorfo de oxazol - pirrolidina, procesos de obtencion y composiciones farmaceuticas.
UY30790A1 (es) Combinacion de dos agentes antiparasitarios, en particular un derivado de 1-aril-4-ciclopropilpirazol y un agente antihelmintico y aplicaciones
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF